The Rising Tide: Competition Law Enforcement in the Indian Pharmaceutical Sector

This article is part of a Chronicle. See more from this Chronicle Kalyani Singh, Nov 24, 2014 Given the sensitivity and direct impact on consumers, it is of little surprise that the pharmaceutical industry—if not an absolute—ranks as one of the most controversial and actively pursued sectors by antitrust authorities across the world. India is […]

NOV-14(2)

In this issue: In the antitrust debate arena, health care topics are the gifts that just keep on giving—always something new to discuss, analyze, or understand. This issue focuses primarily on two segments, product hopping and pay-for-delay. The first paper describes and analyzes, while the next two papers contrast regulatory approaches. Then we present case […]

“Good Luck” Post-Actavis: Current State of Play on “Pay-for-Delay” Settlements

This article is part of a Chronicle. See more from this Chronicle Jonathan Lutinski, Ryan Maddock, Seth Silber, Nov 25, 2014 Chief Justice Roberts’ statement “good luck to the district courts” in his dissent in FTC v. Actavis was certainly prophetic. Since the Court’s issuance of that decision in June 2013, the district courts have been […]

Competition Issues in the Canadian Pharmaceutical Industry

This article is part of a Chronicle. See more from this Chronicle Alan Gunderson, Nov 24, 2014 Health care is a very important sector within the Canadian economy. A recent report estimates total health care spending at CDN $211.2 billion in 2013 which represents 11.2 percent of the Canadian economy or approximately CDN $5,988 per […]

“Product Hopping” on Both Sides of the Pond: A Survey of U.S. and EU Case Law

This article is part of a Chronicle. See more from this Chronicle Michael Frese, Ingrid Vandenborre, Julia York, Nov 24, 2014 In recent years, courts in both the United States and the European Union have increasingly been asked to consider under what circumstances the introduction of a new pharmaceutical drug product harms, rather than benefits, […]

Pharmaceutical Antitrust Complexity

This article is part of a Chronicle. See more from this Chronicle Michael Carrier, Nov 24, 2014 The pharmaceutical industry is unique in its complexity. Markets are nuanced. Multiple regulatory regimes apply. Generic entry is an event with dramatic consequences. These characteristics have encouraged brand-name drug firms to engage in an array of conduct that […]